Menu

アプタマー アフェレシス 核酸医薬の開発｜タグシクス・バイオ株式会社

News Release

rss
2024.3.13
News Release Prof. Yohei Yamauchi of ETH Zurich and TAGCyx Announces a Research Collaboration for the discovery of a novel Xenoligo® aptamer in the field of infectious diseases field.
2024.3.11
News Release Shinji Oki, PhD, at National Center of Neurology and Psychiatry and TAGCyx Announces a research collaboration for the treatment for systemic lupus erythematosus using a novel nucleic acid aptamer.
2024.1.31
News Release SBI Pharmaceuticals and TAGCyx ANNOUNCES A MILESTONE ACHIEVEMENT OF THE RESEARCH AND DEVELOPMENT COLLABORATION OF INNOVATIVE CANCER THERAPY
2024.1.4
News Release TAGCyx and Toray Launch Joint Research Initiative to Combat Preeclampsia during Pregnancy as Part of Efforts to Stem Japan’s Declining Birthrate
2023.12.12
News Release TAGCyx has executed a joint research and development agreement with Teika Pharmaceutical
2022.9.8
News Release CAGE Bio and TAGCyx announced execution of a license agreement for development and commercialization of TAGX-0003 for the treatment of immunodermatology diseases mediated by the IFN-γ pathway
2022.3.23
News Release TAGCyx secured a grant funding from ‘Support Program for Orphan drug prior to the Designation’ of Japan Agency for Medical Research and Development (AMED).
2021.7.7
News Release TAGCyx raises approximately 210 million JPY
2021.3.22
News Release Prof. Shinsuke Sando at　THE UNIVERSITY OF TOKYO and TAGCyx ANNOUNCES THE RESEARCH COLLABORATION of THE TECHNOLOGICAL IMPROVEMENT OF XENOLIGO®
2021.3.5
News Release TAGCyx announces execution of worldwide exclusive supply of proprietary artificial Ds amidite and patent license agreement with Otsuka Chemical Co., Ltd.
2021.2.19
News Release Prof. Taiichi Sakamoto at CHIBA INSTITUTE TECHNOLOGY and TAGCyx ANNOUNCES THE RESEARCH COLLABORATION of THE STRUCTURAL ANALYSIS OF XENOLIGO®
2020.11.25
News Release SBI Pharmaceuticals and TAGCyx ANNOUNCES THE RESEARCH AND DEVELOPMENT COLLABORATION OF INOVATIVE CANCER THERAPY